How metformin works

Chris Triggle, Gnanapragasam Arunachalam and Hong Ding

Chris Triggle, Gnanapragasam Arunachalam and Hong Ding{credit}WCMC-Q{/credit}

Researchers at Weill Cornell Medical College in Qatar (WCMC-Q) have managed to understand how metformin, a widely used oral diabetes drug, interacts with the body to control the blood glucose level.

According to the researchers, metformin works on the ‘longevity gene’ SIRT1 to protect the user’s vascular system against deterioration caused by glucose toxicity.

When the researchers exposed mouse microvascular endothelial cells to high blood glucose levels, they noticed a significant reduction in the expression of SIRT1 and aging of endothelial  cells. Treating the mice with metformin countered this reduction in SIRT1 expression and protected endothelial  cells from this premature aging. However, after knockdown of SIRT1 the mice lost the protective effect produced by metformin. This suggests that the protection the drug offers for diabetes is at least partly due to its effect on the expression of SIRT1.

“The most common cause of death for diabetes patients is vascular and microvascular deterioration – it’s like an advanced aging of the vascular system – so metformin is an extremely useful drug,” said Chris Triggle, professor of pharmacology at WCMC-Q and one of the authors of the research that was published in the British Journal of Pharmacology.

He adds that metformin has long been known to reduce morbidity in patients with diabetes-associated microvascular disease, but that until now the reason for this beneficial effect had not been understood.

In the past, metformin was thought to act by reducing gluconeogenesis – or the formation of glucose from non-carbohydrate sources – in the liver, which in turn would reduce the amount of glucose in the blood and decrease vascular damage. “We realized some years ago that the reported and generally accepted mechanisms of metformin did not really fit with the pharmacokinetic profile – the way the drug interacts with the body – of the drug. Our study proves that metformin does indeed have a direct protective action on the vasculature,” said Triggle.

New hepatitis C treatment may be too expensive

Egypt has the highest hepatitis C burden in the world, with some 14.7% of Egyptians testing positive for HCV antibody. Therefore, it was no surprise that news of the latest oral HCV treatments approved by the FDA in the United States generated quite a buzz in local Egyptian media. The new drugs are very effective and have nearly no side effects, unlike the current regimens that cause depression, anaemia and severe nausea and do not have high success rates.

However, Raymond Schinazi, an Italian-Egyptian pharmacologist who oversaw the development of the new antiviral sofosbuvir which has generated excitement, warned that Egyptians should not be rejoicing just yet, in an interview with the Al-Ahram daily.

The new drug might be too expensive for developing countries, he warns. A 12-week treatment regimen could cost US$86,000 – which is far well more than 0.5 million EGP – much more than most people can afford. With the large number of people needing treatment, it would be impossible for the government to use the new drug instead of its current regimen, in which a full, 48-week course of HCV medication using the antiviral drug ribavirin and interferon costs around US$3,500.

“The drug can save the lives of millions around the world. But at its current price, it can bankrupt developing countries,” Schinazi tells Al-Ahram.

He goes on to stress that most of the studies conducted on sofosbuvir were on genotype 1, which is the genotype most present in North America and Europe. However, it has not been widely tested against genotype 4 which is the predominant one in Egypt and the Middle East.

“The cost of treatment will eventually go down, similar to what happened with antiretroviral treatments for HIV/AIDS. However, I think it may still be a huge burden for Egypt due to the large number of people infected with the virus,” adds Schinazi in his interview.

He goes on to suggest that a more reliable strategy for Egypt would be to invest in medical and pharmacological research and develop it’s own affordable drugs, similar to what countries in Southeast Asia have done. “You spend millions annually to treat a few thousand people and the infection rate is still high. This money should be better managed to improve research and raise awareness to limit new infections.”